Drugs that contain Dacomitinib
1. Drug name - VIZIMPRO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7772243 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
Aug, 2028
(5 years from now) | |
| CN1972688A | PFIZER | 4-Phenylamino-Quinazolin-6-Yl-Amides Compounds |
Apr, 2025
(2 years from now) | |
| CN1972688B | PFIZER | 4-Anilino-Quinazoline-6-Yl-Amide Compound |
Apr, 2025
(2 years from now) | |
| IN244837B | PFIZER | 4-Phenylamino-Quinazolin-6-Yl-Amides And A Pharmaceutical Composition Comprising The Same |
Apr, 2025
(2 years from now) | |
| IN200606238P1 | PFIZER | 4-Phenylamino-Quinazolin-6-Yl-Amides |
Apr, 2025
(2 years from now) | |
| EP1746999B1 | PFIZER | 4-Phenylamino-Quinazolin-6-Yl-Amides |
Apr, 2025
(2 years from now) | |
| EP1746999A1 | PFIZER | 4-Phenylamino-Quinazolin-6-Yl-Amides |
Apr, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623883 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
May, 2025
(2 years from now) | |
Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 15MG | TABLET;ORAL | Prescription |
| 30MG | TABLET;ORAL | Prescription |
| 45MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.